TPP1 promoter mutations cooperate with TERT to drive melanoma telomere elongation

Alder’s team mined cancer mutation databases to identify recurrent TPP1 promoter variants that mirror the known TERT promoter mutations present in roughly 75 percent of melanomas. They then engineered human melanocytes with the individual or combined mutations and measured telomere length by quantitative PCR and Southern blotting over serial passages. Only the dual-mutant cells maintained and extended telomeres beyond the threshold that normally triggers replicative senescence. The finding clarifies why TERT mutations alone have been insufficient to recapitulate patient telomere phenotypes in prior melanocyte models. TPP1 protein stabilizes telomerase processivity at the chromosome end; elevated levels driven by promoter mutations therefore amplify the modest transcriptional boost from TERT variants. This two-hit requirement explains the strong selective pressure observed for both alterations during melanomagenesis. Therapeutically, the work nominates TPP1 itself or its interaction interface with telomerase as a druggable node downstream of the already-targeted TERT promoter. Small-molecule or PROTAC approaches that disrupt TPP1-telomerase binding could shorten telomeres selectively in cells carrying both mutations, sparing normal tissues that lack the promoter lesions. Validation will require CRISPR base-editing of patient-derived xenografts to confirm that reverting either mutation collapses telomere length and impairs tumor growth in vivo.